WuXi Biologics Reports Solid 2023 Interim Results
Revenue Increased by 17.8% Y-o-Y to RMB8,492.0 Million Adjusted Net Profit Rose by 0.4% to RMB2,925.6 Million Non-COVID Revenue Achieved 59.7% Y-o-Y Growth,...
Source: prnewswire.com
Stay updated with breaking news from Separate Listing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Revenue Increased by 17.8% Y-o-Y to RMB8,492.0 Million Adjusted Net Profit Rose by 0.4% to RMB2,925.6 Million Non-COVID Revenue Achieved 59.7% Y-o-Y Growth,...
Net Profit Achieves High Growth of 120.0% to RMB 412.4 Million Highlights of the Annual Results for the Year Ended December 31, 2021: • The continued expansion...